Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Angela Weatherwax

Physician Assistant, Medical Columbus, OH Physician Assistant

NPI 1861486961 CMS profile 10582246

3555 Olentangy River Rd, Columbus, OH 43214

Open in the dashboard

General payments

$10,366

530 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Weatherwax of Columbus, OH is reported in the CMS Open Payments database as having received $10,366 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,786 90
2024 General $2,065 92
2023 General $2,976 144
2022 General $2,359 129
2021 General $1,180 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Weatherwax
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Angela Weatherwax were reported at $1,786. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Angela Weatherwax Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,180 $156 $41–$563 $132
2022 $2,359 $185 $55–$649 $149
2023 $2,976 $199 $58–$717 $160
2024 $2,065 $206 $62–$740 $164
2025 $1,786 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,541 179 payments
  2. Boston Scientific Corporation $1,687 81 payments
  3. Collegium Pharmaceutical, Inc. $692 39 payments
  4. Pfizer Inc. $667 39 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $605 36 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $526 28 payments
  7. SI-BONE, Inc. $410 4 payments
  8. Biohaven Pharmaceuticals, Inc. $395 18 payments
  9. Scilex Pharmaceuticals Inc. $371 17 payments
  10. IBSA Pharma Inc. $354 21 payments
  11. Other $2,119 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,317 523 payments
  2. Education $49 7 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $1,346 95 payments
  2. UBRELVY $1,233 84 payments
  3. NURTEC ODT Primary Care $922 46 payments
  4. NURTEC ODT Pain $667 39 payments
  5. RELISTOR $552 33 payments
  6. XTAMPZA $537 31 payments
  7. BOTOX $403 19 payments
  8. General - Therapies $377 14 payments
  9. Licart $304 18 payments
  10. ZTLido $297 13 payments
  11. Other $4,061 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

996

Median for Physician Assistant: 241

Drug cost

$34,431

Median for Physician Assistant: $4,110

Branded share of claims

37.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 17 $9,787
Fentanyl Generic 58 $7,081
Buprenorphine Generic 15 $4,081
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 147 $3,670
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 112 $1,971
Morphine Sulfate Er Morphine Sulfate Brand 95 $1,913
Gabapentin Generic 126 $1,558
Oxycodone Hcl Generic 84 $1,172
Tizanidine Hcl Generic 141 $915
Cyclobenzaprine Hcl Generic 57 $700

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$22,762

Medicare's payments for the services billed

Medicare patients

90

Average age 72

Services billed

1,073

55 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 40%
Diabetes 33%
Chronic kidney disease 29%
Ischemic heart disease 28%
COPD 27%
Heart failure 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $214
$214 — —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $144
$144 — —
BOTOX
  • AbbVie, Inc. $135
$135 — —
QULIPTA
  • AbbVie, Inc. $131
$131 — —
UBRELVY
  • AbbVie, Inc. $127
$127 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record